The use of the latest generation of orlistat in drug therapy of obesity

• Pavel S. Zubeev
• Podprugina N.G.

Abstract

Since obesity is a chronic recurrent disease that requires long-term complex therapy, high requirements for efficacy and safety are imposed on drugs for its treatment. Currently, orlistat is the safest means, because it is not absorbed into the blood and does not have a systemic effect. It is included in both the Russian recommendations and international standards for the treatment of obesity. However, due to side effects from the gastrointestinal tract, which develop in almost half of the patients with orlistat, the full course of therapy is rarely maintained for at least six months.

As an auxiliary component, gum arabic (acacia gum), which forms a stable emulsion with undigested fats in the intestinal lumen, is included in the drug Listata (international non-proprietary name - orlistat), which significantly reduces the side effects of the gastrointestinal tract, as shown in the results of the All-Russian Observation Program.

Keywords:obesity, treatment, orlistat

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)